logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

SABCS 2019 – HER2+ breast cancer: add-on pertuzumab shows clinically relevant benefit in some patients

4.5% increase in invasive DFS in node-positive subgroup did not meet significance but still relevant.